# Autologous CAR-T Cells (WD-01) for Metastatic Colorectal Cancer

> **NCT06675513** · EARLY_PHASE1 · SUSPENDED · sponsor: **Wondercel Biotech (ShenZhen)** · enrollment: 30 (estimated)

## Conditions studied

- CRC (Colorectal Cancer)
- Metastatic Colorectal Cancer

## Interventions

- **BIOLOGICAL:** An armored GCC targeting WD-01 CAR-T to treat cancer patients Other Name:

## Key facts

- **NCT ID:** NCT06675513
- **Lead sponsor:** Wondercel Biotech (ShenZhen)
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2025-05-18
- **Primary completion:** 2027-12-30
- **Final completion:** 2029-12-30
- **Target enrollment:** 30 (ESTIMATED)
- **Why stopped:** Because the implementation of the new regulation policy by the Chinese authority
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06675513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06675513, "Autologous CAR-T Cells (WD-01) for Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06675513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*